ATXI (Avenue Therapeutics) 3-Year Book Growth Rate : -80.60% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics 3-Year Book Growth Rate?

Avenue Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $1.33.

During the past 12 months, Avenue Therapeutics's average Book Value per Share Growth Rate was -71.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was -80.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was -68.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Avenue Therapeutics was -48.80% per year. The lowest was -80.60% per year. And the median was -63.65% per year.

Competitive Comparison of Avenue Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Avenue Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avenue Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Avenue Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Avenue Therapeutics (OTCPK:ATXI) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Avenue Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Avenue Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (OTCPK:ATXI) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

49Y:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Executives

Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Jay D Kranzler	director	4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc.	10 percent owner	SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean	officer: Chief Executive Officer	C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin	officer: Int. PEO, Int. PFO, and COO	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Curtis Gale Oltmans	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Lucy Lu	director, officer: President, CEO	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram	director	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore	director	C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena	director	CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay	director	CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008